Articles related to PEER-TO-PEER
Leqembi: What Physicians Need to Know About the New Alzheimer’s Drug
Leqembi, a newly FDA-approved drug, has shown promising results in clinical trials, resulting in a 28% slower decline in Alzheimer’s patients compared to placebo. This equates to an additional four to five months of retained function.
Neurology November 7th 2023
Perspective: Standard of Care
In addition to being stigmatized and vulnerable, people with intellectual or developmental disabilities are severely undercounted and underrepresented in medical research. This highlights the urgent need for more inclusive research and resources to ensure equitable cancer treatment for this population.
Internal Medicine November 1st 2023
Our Practice Management Decisions that Seemed Questionable at First but Worked Out Great
Did you know that over-hiring doctors can lead to more innovative opportunities within your practice? Dr. Laurie Sorrenson’s experience proves that what may initially seem like an excessive decision can turn out to be a fantastic move.
Optometry October 30th 2023
Why Anesthetists are Calling for an Extraordinary Meeting on Anesthesia Associates
Delve deeper into this issue and consider its potential implications for our healthcare system. Your insights and perspectives could contribute significantly to this important debate.
Anesthesiology October 19th 2023